PH12022550181A1 - Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions - Google Patents
Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditionsInfo
- Publication number
- PH12022550181A1 PH12022550181A1 PH1/2022/550181A PH12022550181A PH12022550181A1 PH 12022550181 A1 PH12022550181 A1 PH 12022550181A1 PH 12022550181 A PH12022550181 A PH 12022550181A PH 12022550181 A1 PH12022550181 A1 PH 12022550181A1
- Authority
- PH
- Philippines
- Prior art keywords
- tmem16a
- modulators
- treatment
- pyridine derivatives
- respiratory conditions
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 102000003787 Anoctamin-1 Human genes 0.000 abstract 1
- 108090000160 Anoctamin-1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1910607.9A GB201910607D0 (en) | 2019-07-24 | 2019-07-24 | Compounds |
| GBGB2005739.4A GB202005739D0 (en) | 2020-04-20 | 2020-04-20 | Compounds |
| PCT/GB2020/051778 WO2021014166A1 (en) | 2019-07-24 | 2020-07-24 | Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022550181A1 true PH12022550181A1 (en) | 2023-01-16 |
Family
ID=71948615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/550181A PH12022550181A1 (en) | 2019-07-24 | 2020-07-24 | Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220235006A1 (enExample) |
| EP (1) | EP4003516A1 (enExample) |
| JP (1) | JP7583022B2 (enExample) |
| KR (1) | KR20220063162A (enExample) |
| CN (1) | CN114616226B (enExample) |
| AU (1) | AU2020317036A1 (enExample) |
| BR (1) | BR112022001164A2 (enExample) |
| CA (1) | CA3145120A1 (enExample) |
| CL (1) | CL2022000147A1 (enExample) |
| CO (1) | CO2022002022A2 (enExample) |
| CR (1) | CR20220072A (enExample) |
| IL (1) | IL290035A (enExample) |
| MX (1) | MX2022000841A (enExample) |
| PE (1) | PE20221441A1 (enExample) |
| PH (1) | PH12022550181A1 (enExample) |
| WO (1) | WO2021014166A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221441A1 (es) * | 2019-07-24 | 2022-09-21 | Tmem16A Ltd | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
| KR20260025059A (ko) * | 2024-08-13 | 2026-02-23 | 전남대학교산학협력단 | 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176767A1 (en) * | 2003-10-30 | 2005-08-11 | Laval Chan Chun Kong | Pyridine carboxamide and methods for inhibiting HIV integrase |
| EP3612180B1 (en) * | 2017-04-17 | 2023-10-11 | The Regents of the University of California | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a |
| GB201801355D0 (en) * | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| PE20221441A1 (es) * | 2019-07-24 | 2022-09-21 | Tmem16A Ltd | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
-
2020
- 2020-07-24 PE PE2022000119A patent/PE20221441A1/es unknown
- 2020-07-24 EP EP20751234.4A patent/EP4003516A1/en active Pending
- 2020-07-24 KR KR1020227006371A patent/KR20220063162A/ko not_active Ceased
- 2020-07-24 BR BR112022001164A patent/BR112022001164A2/pt not_active Application Discontinuation
- 2020-07-24 CN CN202080053192.6A patent/CN114616226B/zh active Active
- 2020-07-24 PH PH1/2022/550181A patent/PH12022550181A1/en unknown
- 2020-07-24 CR CR20220072A patent/CR20220072A/es unknown
- 2020-07-24 WO PCT/GB2020/051778 patent/WO2021014166A1/en not_active Ceased
- 2020-07-24 AU AU2020317036A patent/AU2020317036A1/en not_active Abandoned
- 2020-07-24 JP JP2022504089A patent/JP7583022B2/ja active Active
- 2020-07-24 CA CA3145120A patent/CA3145120A1/en active Pending
- 2020-07-24 MX MX2022000841A patent/MX2022000841A/es unknown
-
2022
- 2022-01-21 US US17/581,504 patent/US20220235006A1/en active Pending
- 2022-01-21 CL CL2022000147A patent/CL2022000147A1/es unknown
- 2022-01-23 IL IL290035A patent/IL290035A/en unknown
- 2022-02-24 CO CONC2022/0002022A patent/CO2022002022A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220072A (es) | 2022-06-29 |
| MX2022000841A (es) | 2022-06-08 |
| WO2021014166A1 (en) | 2021-01-28 |
| CL2022000147A1 (es) | 2022-10-07 |
| PE20221441A1 (es) | 2022-09-21 |
| JP2022541311A (ja) | 2022-09-22 |
| KR20220063162A (ko) | 2022-05-17 |
| IL290035A (en) | 2022-03-01 |
| CO2022002022A2 (es) | 2022-06-10 |
| CA3145120A1 (en) | 2021-01-28 |
| US20220235006A1 (en) | 2022-07-28 |
| AU2020317036A1 (en) | 2022-03-17 |
| JP7583022B2 (ja) | 2024-11-13 |
| CN114616226A (zh) | 2022-06-10 |
| CN114616226B (zh) | 2025-03-04 |
| EP4003516A1 (en) | 2022-06-01 |
| BR112022001164A2 (pt) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| PH12020551327A1 (en) | Compounds | |
| PH12020500509A1 (en) | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | |
| MX2020001833A (es) | Moduladores de piruvato quinasas y uso de los mismos. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| DE602004019198D1 (de) | Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege | |
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| MX2015001720A (es) | Hetero-azepinonas sustituidas. | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| PH12020552206A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
| DK2215058T3 (da) | Substituerede N-phenylbipyrrolidinureaer og terapeutisk anvendelse deraf | |
| MD20150075A2 (ro) | Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale | |
| MY209256A (en) | Compounds affecting pigment production and use thereof for treatment of bacterial diseases | |
| MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| EA201891377A1 (ru) | ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ | |
| EA201991253A1 (ru) | Бензодиазолиевые соединения в качестве ингибиторов enac | |
| PH12022550078A1 (en) | Enzyme inhibitors | |
| EP4427815A3 (en) | Deuterium-enriched pirfenidone and methods of use thereof | |
| PH12022550181A1 (en) | Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions | |
| CL2024000742A1 (es) | Compuestos moduladores de gpr52 | |
| WO2019040104A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES | |
| PH12016501645A1 (en) | Aminopyrazolone derivative |